-
EP2906252
European procedure
Extract from the Register of European Patents
EP About this file: EP2906252
| EP2906252 - PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 20.04.2018 Database last updated on 16.05.2026 | |
| Former | The patent has been granted Status updated on 12.05.2017 | ||
| Former | Grant of patent is intended Status updated on 22.12.2016 | Most recent event Tooltip | 20.04.2018 | No opposition filed within time limit | published on 23.05.2018 [2018/21] | Applicant(s) | For all designated states ADC Therapeutics SA Route de la Corniche 3B 1066 Epalinges / CH | For all designated states Medimmune Limited Milstein Building Granta Park Cambridge, Cambridgeshire CB21 6GH / GB | [2017/24] |
| Former [2017/11] | For all designated states ADC Therapeutics SA route de la Corniche 3B 1066 Epalinges / CH | ||
| For all designated states Medimmune Limited Milstein Building Granta Park Cambridge, Cambridgeshire CB21 6GH / GB | |||
| Former [2015/34] | For all designated states ADC Therapeutics S.a.r.l. Rue Saint-Pierre 2 1003 Lausanne / CH | ||
| For all designated states Medimmune Limited Milstein Building Granta Park Cambridge, Cambridgeshire CB21 6GH / GB | Inventor(s) | 01 /
VAN BERKEL, Patricius Hendrikus Cornelis ADC Therapeutics Sàrl Rue Saint-Pierre 2 C/O Michael Forer 1003 Lausanne / CH | 02 /
HOWARD, Philip Wilson Spirogen Limited The QMB Innovation Centre 42 New Road London Greater London E1 2AX / GB | [2015/34] | Representative(s) | Watson, Robert James, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | [2015/34] | Application number, filing date | 13788691.7 | 11.10.2013 | [2015/34] | WO2013EP71343 | Priority number, date | US201261712924P | 12.10.2012 Original published format: US 201261712924 P | US201261712928P | 12.10.2012 Original published format: US 201261712928 P | US201361784270P | 14.03.2013 Original published format: US 201361784270 P | US201361784233P | 14.03.2013 Original published format: US 201361784233 P | US201361784249P | 14.03.2013 Original published format: US 201361784249 P | [2015/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014057115 | Date: | 17.04.2014 | Language: | EN | [2014/16] | Type: | A1 Application with search report | No.: | EP2906252 | Date: | 19.08.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.04.2014 takes the place of the publication of the European patent application. | [2015/34] | Type: | B1 Patent specification | No.: | EP2906252 | Date: | 14.06.2017 | Language: | EN | [2017/24] | Search report(s) | International search report - published on: | EP | 17.04.2014 | Classification | IPC: | A61K47/68, A61P35/00, // C07K16/32, A61K39/395, A61K31/551 | [2017/24] | CPC: |
C07K16/32 (EP,US);
A61K31/551 (EP,US);
A61K47/6801 (EP,US);
A61K47/6855 (EP,US);
A61P35/00 (EP);
A61P43/00 (EP);
A61K2039/505 (EP,US)
(-)
|
| Former IPC [2017/01] | A61K47/48, A61P35/00, // C07K16/32, A61K39/395, A61K31/551 | ||
| Former IPC [2015/34] | A61K47/48, A61P35/00, C07K16/30, A61K39/395, A61K31/551 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/34] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | PYRROLOBENZODIAZEPIN-ANTI-HER2-ANTIKÖRPERKONJUGATE | [2015/34] | English: | PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES | [2015/34] | French: | CONJUGUÉS ANTICORPS ANTI-HER2 - PYRROLOBENZODIAZÉPINE | [2015/34] | Entry into regional phase | 06.05.2015 | National basic fee paid | 06.05.2015 | Designation fee(s) paid | 06.05.2015 | Examination fee paid | Examination procedure | 06.05.2015 | Amendment by applicant (claims and/or description) | 06.05.2015 | Examination requested [2015/34] | 01.04.2016 | Despatch of a communication from the examining division (Time limit: M06) | 27.09.2016 | Reply to a communication from the examining division | 23.12.2016 | Communication of intention to grant the patent | 27.04.2017 | Fee for grant paid | 27.04.2017 | Fee for publishing/printing paid | 27.04.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 01.04.2016 | Opposition(s) | 15.03.2018 | No opposition filed within time limit [2018/21] | Fees paid | Renewal fee | 26.10.2015 | Renewal fee patent year 03 | 24.10.2016 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YDA] WO2011130598 (SPIROGEN LTD et al.) [YD] 1-99,101-116 * page 149; compound 80 * * pages 193-194; table 1; compounds 105,106,114,115 * * page 197, line 17 - page 200, line 24 * * figures 1a,1b; compounds 15ba, 15bb,15d, 58 * * figures 2-5 * * claim - *[A] 100 | [YDA] WO2011130613 (SEATTLE GENETICS INC et al.) [YD] 1-99,101-116 * page 50, line 29 * * page 90; compound 30 * * page 105; compound 51 *[A] 100 | [YDA] WO2011130616 (SPIROGEN LTD et al.) [YD] 1-99,101-116 * page 50, line 28 * * page 87; compound 26 * * page 89; compound 30 * * page 90; compound 31 *[A] 100 | [YA] WO2011137245 (ESPERANCE PHARMACEUTICALS INC et al.) [Y] 1-99,101,102,105-116 * paragraph [0063]; sequence VH * * paragraph [0064]; sequence VL * * paragraph [0065] *[A] 100 | [YA] US2008112961 (STAVENHAGEN JEFFREY B et al.) [Y] 1-99,102,105-116 * paragraph [0309] * * sequence 34 *[A] 100 | [YA] WO2010151793 (FIVE PRIME THERAPEUTICS INC et al.) [Y] 1-99,101-116 * example 1; sequences 2,5 *[A] 100 | [YPA] WO2013055987 (SPIROGEN SARL et al.) [YP] 1-99,101-116 * page 84; compound 14 * * page 88; compound 22 * * page 93; compounds 101,102,104,110,111 * * page 95, line 1 - page 97, line 5 * * figures 1,2 *[A] 100 | [AP] WO2012153193 (LEGOCHEM BIOSCIENCES INC et al.) [AP] 1-116 * page 62, compound LCB14-0577 * * page 66, compound LCB14-0578 * * page 68, compound LCB14-0582 * * page 71, compound LCB14-0594 * * page 73, compound LCB14-0596 * * page 77, compound LCB14-0597 * * page 79, compound LCB14-0599 * * example 1.1 * | [T] WO2013177481 (IMMUNOGEN INC et al.) [T] 1-116 * page 71, line 23 * * page 95, formula at the bottom * * page 96, formula at the top * |